title: In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer.
abstract: Multiple different approaches are being used to activate the immune system against breast cancer. Vaccine therapy in general follows the principle that injections of various substances ultimately result in the presentation of tumor peptides to the patient's immune system. We proposed a potential in silico DNA vaccine against breast cancer by integrating high affinity T cell (MHC-I and MHC-II) and B cell (continuous and discontinuous) epitopes. The matching of the HLA haplotype and antigen was performed to provide the appropriate peptide epitope suitable for majority of the patients. The immunogenic nature of the antigenic construct was also enhanced by the administration of consensus epitopes. The potency of DNA vaccines depends on the efficient expression and presentation of the encoded antigen of interest and the chances of efficient expression of our antigenic construct in host organism was also verified by in silico approaches. An attempt was made to overcome the limited potency of the DNA vaccine by targeting DNA to professional antigen-presenting cells (APCs). A higher immune response theoretically corresponds to a higher survival rate of patients. Therefore, optimization studies were also employed to enhance the immunogenicity of proposed in silico DNA vaccine.
authors.affiliation: Centre of Bioinformatics, School of Biotechnology, Shri Mata Vaishno Devi (SMVD) University, Jammu, Jammu and Kahmir, 182320, India. urvashi.baloria@gmail.com
authors.forename: Urvashi
authors.initials: U
authors.lastname: Baloria
authors.forename: Bashir Akhlaq
authors.initials: BA
authors.lastname: Akhoon
authors.forename: Shishir Kumar
authors.initials: SK
authors.lastname: Gupta
authors.forename: Sujata
authors.initials: S
authors.lastname: Sharma
authors.forename: Vijeshwar
authors.initials: V
authors.lastname: Verma
mesh_terms: D000595:Amino Acid Sequence; D001943:Breast Neoplasms / Q000276:immunology / Q000517:prevention & control*; D019496:Cancer Vaccines / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D018604:Epitope Mapping; D018985:Epitopes, B-Lymphocyte / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D005260:Female; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D040901:Proteomics / Q000295:instrumentation / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000737:chemistry* / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000737:chemistry / Q000235:genetics / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D018985:Epitopes, B-Lymphocyte; D018984:Epitopes, T-Lymphocyte; D018719:Erb-b2 Receptor Tyrosine Kinases; D019444:Vaccines, DNA; C508053:ERBB2 protein, human